RT Journal Article
T1 Anti-CD137 and PD-1/PD-L1 Antibodies En Route toward Clinical Synergy.
A1 Pérez-Ruiz, Elisabeth
A1 Etxeberria, Iñaki
A1 Rodriguez-Ruiz, Maria E
A1 Melero, Ignacio
AB T-cell costimulation and coinhibition can be respectively exploited by blocking and agonist mAbs. Both strategies can be synergistically combined in mouse models. Early clinical results from combinations of anti-PD-1 mAbs in conjunction with agonist anti-CD137 (4-1BB) mAbs show excellent safety and promising efficacy. Clin Cancer Res; 23(18); 5326-8. ©2017 AACRSee related article by Tolcher et al., p. 5349.
YR 2017
FD 2017-08-08
LK https://hdl.handle.net/10668/26705
UL https://hdl.handle.net/10668/26705
LA en
DS RISalud
RD Apr 11, 2025